A grave warning on measles

The smartest thinkers in life sciences on what's happening — and what's to come.

March 17, 2024 Check out STAT+

Sponsored By

By Alexa Lee Newsletter Strategist

Good morning! Alexa — STAT's newsletter strategist — here. I'm writing to you in Torie's place because she has started parental leave a little earlier than she anticipated! Given this incredible news, Torie will be stepping away from this newsletter for a while — and former First Opinion editor Pat Skerrett will be steering the ship in the coming weeks. Please continue to share your Letters to the Editor here, and any submissions to First Opinion here. Recommendation of the week: In Torie's absence, I'll let this week's essays speak for themselves, but I will include my own cheeky little rec! Every morning for the past week I've been listening to "T.O.N.Y." by Solange to remind myself of the importance of being a little bit groovy. Thanks for reading!

UNIOR KANNAH/AFP via Getty Images No parent who has seen the children I've treated for measles would refuse a vaccine As measles makes a comeback in the U.S., I wish more anti-vaccine parents would learn about the children I've treated. By Paul Law Prescription for resilience: Health care needs financial sector-inspired regulation U.S. health care's critical technology infrastructure needs to be bolstered by strong regulation that stress-tests against cyberattacks. By Jonathan Slotkin and David Vawdrey Lessons for scientists from the All of Us Research Program backlash Too often, scientists fail to grasp the societal impacts of their research — often to the detriment of the people they attempt to help. By Thiago Arzua Adobe Disabled scientists are often left out of academia. The NIH can help change that Disabled researchers like us offer innovation, problem solving, and insight. But too often, they are left out of academia. By Elizabeth Weaver II and Kiana Jackson STAT+ | Good health care price transparency rules are at risk if Congress doesn't act Recently adopted health care price transparency rules are at risk of getting bogged down by regulatory malaise. By Benjamin Chartock

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying First Opinion? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser